In the past 10 years, high throughput sequencing of adaptive repertoires has accelerated in vitro selections, in vivo immunizations, and downstream bioengineering and de-risking of of monoclonal leads. The AbGenesis repertoire analysis and engineering environment enables the analysis of individual cells to millions of B-cell and T-cell receptors, as well as linking of sequence and phenotype (affinity, expression efficiency, stability) data.

AbGenesis is the world's leading platform for antibody and immune repertoire sequence analysis. In a simple to use environment users can interrogate sequence data and derive meaningful and decisionable insights from their data. From identifying candidate clones, analyzing CDR diversity and guiding engineering decisions AbGenesis enables all facets of antibody discovery. Common uses include analyzing library selections, hybridoma and immunization data for discovery or monitor population immune responses.


The platform accepts read data from any common platform including Sanger, MiSeq, HiSeq, 454, Ion Torrent, and public patent and structural databases. By using profile Hidden Markov Models as the core immunoglobulin-recognizing algorithm, AbGenesis is able to analyze human, mouse, rat, camelid, shark, dog, cat, cow, horse, pig, rhesus, cyno, chicken, and multiple other model organisms or engineered immunoglobulin constructs without constraints of codon usage or species of origin.

Built in 2012, it immediately attracted multiple clients and enabled us to become profitable in our first year of business without ever needing venture funding. AbGenesis is now used at over 35 institutions and biotechnology companies, including 7 of the 10 top pharma. Internally, AbGenesis acts synergistically to empower our antibody library design, antibody discovery, and vaccine optimization programs.

abgenesis platform explanation


Thanks! Message sent.